Grace Therapeutics Reports Promising Drug Development Progress

Acasti Pharma, Inc. ( (GRCE) ) has released its Q4 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors.

Grace Therapeutics, Inc., formerly known as Acasti Pharma, Inc., is a pharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies. The company aims to enhance clinical outcomes through proprietary formulations applied to existing pharmaceutical compounds.

In its latest earnings report, Grace Therapeutics highlighted significant progress in its drug development pipeline, particularly with its lead drug candidate, GTx-104. The company has completed a pivotal Phase 3 trial for GTx-104, showing promising results in treating aneurysmal subarachnoid hemorrhage (aSAH), a rare type of stroke.

Key financial and strategic highlights include the successful completion of the STRIVE-ON trial, where GTx-104 demonstrated a reduction in clinically significant hypotension compared to oral nimodipine. The trial also showed favorable outcomes in terms of dose intensity, patient recovery, and reduced ICU stays. Grace Therapeutics plans to submit a New Drug Application (NDA) for GTx-104 in 2025.

Additionally, the company is advancing its other drug candidates, GTx-102 and GTx-101, targeting ataxia-telangiectasia and postherpetic neuralgia, respectively. Both candidates have shown promising clinical data, and further development is contingent on additional funding or partnerships.

Looking forward, Grace Therapeutics is optimistic about its pipeline’s potential to address unmet medical needs in rare diseases. The management remains focused on regulatory submissions and strategic partnerships to enhance shareholder value and bring innovative therapies to market.